China Universal Asset Management Co. Ltd. Sells 2,401 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

China Universal Asset Management Co. Ltd. cut its position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 29.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 5,892 shares of the company’s stock after selling 2,401 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in BeOne Medicines were worth $2,007,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ONC. Primecap Management Co. CA bought a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $1,231,720,000. Temasek Holdings Private Ltd purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $244,603,000. Marshall Wace LLP bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $113,190,000. Baird Financial Group Inc. purchased a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $73,347,000. Institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price for the company in a research report on Monday, January 12th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Citigroup upped their price target on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Truist Financial set a $400.00 price target on shares of BeOne Medicines in a research note on Monday, November 24th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $381.46.

BeOne Medicines Stock Down 1.3%

NASDAQ:ONC opened at $354.48 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. The firm has a market cap of $38.87 billion, a PE ratio of 695.06 and a beta of 0.52. The company has a 50-day moving average of $332.21 and a 200 day moving average of $328.28. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $196.45 and a 1-year high of $385.22.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of BeOne Medicines stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total value of $895,544.30. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 105,283 shares of company stock valued at $32,463,041. Company insiders own 6.62% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.